CollaGenex Pharmaceuticals to Present at the SG Cowen 25th Annual Heal

    Business Editors/Health/Medical Writers
    SG Cowen 25th Annual Health Care Conference

    NEWTOWN, Pa.--(BUSINESS WIRE)--March 7, 2005--CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that Colin Stewart, president and chief executive officer, will present at the SG Cowen 25th Annual Health Care Conference. The presentation is scheduled for 10:30 a.m. ET on Tuesday, March 15, 2005, at the Boston Marriott Copley Place Hotel.
    The presentation will be available as a live audio and visual webcast on the company's website at www.collagenex.com. A replay of this presentation will be available for 90 days at the aforementioned URL.
    CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on providing innovative medical therapies to the dental and dermatology markets. Currently, the Company's professional dental pharmaceutical sales force markets Periostat, which is indicated as an adjunct to scaling and root planing for the treatment of adult periodontitis. Periostat is the first and only pharmaceutical to treat periodontal disease by inhibiting the enzymes that destroy periodontal support tissues and by enhancing bone protein synthesis. The dental sales force also promotes Atridox(R), Atrisorb FreeFlow(R) and Atrisorb-D FreeFlow(R), Atrix Laboratories, Inc.'s products for the treatment of adult periodontitis, to the dental market. The Company's professional dermatology sales force markets Pandel(R), a prescription topical corticosteroid licensed from Altana, Inc.
    Research has shown that certain unique properties of the tetracyclines discovered during the development of Periostat may be applicable to other diseases involving inflammation and/or destruction of the body's connective tissues. CollaGenex is further evaluating Periostat and other IMPACS(R) compounds, including Oracea(TM), to assess whether they are safe and effective in these other applications. Oracea is currently in Phase III clinical trials to evaluate its effectiveness in treating rosacea, a dermatological condition. In addition, CollaGenex has licensed the Restoraderm(R) technology, a unique, proprietary dermal drug delivery system, and plans to develop a range of topical dermatological products with enhanced pharmacologic and cosmetic properties.
    To receive additional information on the Company, please visit our Web site at www.collagenex.com.

    Periostat is a registered trademarks of CollaGenex Pharmaceuticals, Inc.

    All other trade names, trademarks or service marks are the property of their respective owners and are not the property of CollaGenex Pharmaceuticals, Inc. or any of our subsidiaries.

    Pandel is a trademark of Taisho Pharmaceuticals.

    Atridox, Atrisorb and Atrisorb-D are registered trademarks of Atrix Laboratories, Inc.

--30--SF/ph*

CONTACT: CollaGenex Pharmaceuticals, Inc. Nancy C. Broadbent, 215-579-7388 or Financial Dynamics Evan Smith, CFA / Erica Pettit 212-850-5606 / 212-850-5614

KEYWORD: MASSACHUSETTS PENNSYLVANIA TRACK INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL DEVICES MEDICAL TRADESHOW SOURCE: CollaGenex Pharmaceuticals, Inc.

Copyright Business Wire 2005